Canopy Growth’s Twin Headlines: A Brand Refresh Meets a Policy-Driven Selloff

Canopy Growth shares surged on historic US medical cannabis rescheduling but quickly reversed, while the company launches a Tweed brand overhaul to defend Canadian market share.

The past week has delivered a mixed bag for Canopy Growth, as a long-awaited US regulatory shift collided with the harsh realities of the company’s financial position. While a historic rescheduling of medical cannabis in the United States briefly sent shares soaring, the rally quickly evaporated, leaving latecomers nursing losses. At the same time, the company rolled out a major overhaul of its flagship Tweed brand, hoping to claw back market share in its home market.

A Policy Bombshell That Fizzled

On April 23, the US Department of Justice ordered the reclassification of federally licensed medical marijuana products to the less restrictive Schedule III category. The move, the most significant shift in US drug policy in decades, would eliminate the punitive 280E tax burden for licensed operators — a change worth billions in potential savings across the industry. It also opens new avenues for medical research.

But the decision stops well short of full legalization. Recreational cannabis remains illegal at the federal level, and as a Nasdaq-listed company, Canopy Growth still cannot directly own US cannabis operations. Its economic interest in the subsidiary Canopy USA remains off its balance sheet for now.

The market initially cheered the news. Canopy’s stock had already surged roughly 70 percent from late March, hitting a high of around C$1.51 (US$1.10) on the day of the announcement. But the euphoria was short-lived. The stock opened near that peak and then reversed sharply, closing the session at roughly C$1.24. By Friday, April 24, it had slipped further to about C$1.19, down more than 3 percent on the day.

Chart watchers now eye the support zone between C$1.15 and C$1.20. A break below that level could open the door to a test of the C$1.00 mark, with the late-March low near C$0.86 serving as the ultimate floor. On the upside, resistance sits firmly in the C$1.50 to C$1.60 range.

Tweed Gets a Summer Makeover

Amid the stock market drama, Canopy Growth unveiled a comprehensive refresh of its Tweed brand on April 23. New packaging with see-through windows, lower price points, and three new flower strains — Tropical Gelato Slushie, Citrus Candy Cake, and GMO Jet Fuel — aim to reignite consumer interest. The summer campaign, “There’s a Tweed for That,” launches over the Victoria Day weekend, the traditional start of Canada’s summer season.

The revamped lineup includes whole flower, milled flower, vapes, and softgels, with a new milled format slated for later in the summer of 2026. For a company that has struggled to hold shelf space, the Tweed relaunch is about more than aesthetics — it’s a bid to defend market share in an increasingly crowded market.

The Numbers Tell a Story of Progress — and Pain

The operational picture remains challenging, though there are signs of improvement. In the December 2025 quarter (Canopy’s fiscal third quarter), consolidated net revenue came in at C$75 million, roughly flat year-over-year. The net loss narrowed to about C$62.6 million, half the level of a year earlier. Adjusted EBITDA losses shrank 17 percent to C$3 million, marking the third consecutive quarter of improvement.

Free cash outflow improved to C$19.0 million from C$28.2 million a year ago. The company ended the quarter with C$371 million in cash and a net liquidity position of C$146 million — the strongest balance sheet since fiscal 2022. A recapitalization in January 2026 pushed all debt maturities out to at least January 2031, though it diluted existing shareholders through the issuance of new equity.

Still, the core business remains under water. The December quarter saw a net loss of roughly C$62 million on revenue of about C$90 million. Canopy has not reported a profitable quarter since 2017. The company has realized annualized cost savings of C$29 million since March 2025, but margins remain deeply negative.

What Comes Next

The next major catalyst for the sector is a hearing before the US Drug Enforcement Administration on June 29, which will determine the final implementation of the Schedule III reclassification. Until then, Canopy must prove it can operate on its own merits, without relying on political headlines.

The Tweed relaunch and the balance sheet improvements offer some reasons for cautious optimism. But the stock’s violent reaction to the US policy news underscores a fundamental truth: the market is still waiting for Canopy to show it can generate sustainable profits, not just regulatory tailwinds.